Worg Pharmaceuticals (Zhejiang) Co., Ltd., a China-based biopharmaceutical company specializing in the development of immunotherapies for allergic and autoimmune diseases, has successfully raised hundreds of millions of renminbi in a new financing round. The round saw participation from notable investors such as PICC Investment, Tsing Song Capital, and an undisclosed renowned industry investment institution.
Global Expansion and Commercial Presence
Founded in 2018, Worg Pharmaceuticals has established a strong business presence in Europe with a subsidiary in Basel, complementing its domestic operations. The company boasts a portfolio of dozens of commercialized products and is actively expanding its global footprint. In addition to its expansion efforts, Worg Pharma is advancing the clinical development and commercialization of innovative allergy immunotherapy products that are already listed in Europe.
Innovative Technology Platforms and Clinical Progress
The establishment of technology platforms PCFiT and Apitope has enabled Worg Pharmaceuticals to rapidly build a research and development pipeline focused on allergy and autoimmune disease indications. The company has made significant strides in clinical trials, with its grass pollen allergy and Graves’ disease pipelines having entered Phases II and III, respectively, in various countries around the world. This progress underscores Worg Pharma’s commitment to bringing effective immunotherapies to patients globally.-Fineline Info & Tech
Leave a Reply